Considering the role of RAGE and its ligands on promoting a pro-inflammatory tumor microenvironment, it’s likely that alterations of RAGE signaling pathway may also impact the efficacy of immunotherapies for malignant gliomas. This evidence concerns the gene AGER and malignant glioma.